0001213900-23-087747.txt : 20231116 0001213900-23-087747.hdr.sgml : 20231116 20231116093831 ACCESSION NUMBER: 0001213900-23-087747 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20231116 FILED AS OF DATE: 20231116 DATE AS OF CHANGE: 20231116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Incannex Healthcare Ltd CENTRAL INDEX KEY: 0001873875 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41106 FILM NUMBER: 231412680 BUSINESS ADDRESS: STREET 1: 401 DOCKLANDS DRIVE STREET 2: SUITE 15, LEVEL 12 CITY: DOCKLANDS, VICTORIA STATE: C3 ZIP: 3008 BUSINESS PHONE: 61 409 840 786 MAIL ADDRESS: STREET 1: 401 DOCKLANDS DRIVE STREET 2: SUITE 15, LEVEL 12 CITY: DOCKLANDS, VICTORIA STATE: C3 ZIP: 3008 6-K 1 ea188588-6k_incannex.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of November, 2023

 

Commission File Number: 001-41106

 

 

 

Incannex Healthcare Limited

(Exact name of Registrant as specified in its charter)

 

 

 

not applicable

(Translation of Registrant’s name into English)

 

Australia

(Jurisdiction of incorporation or organization)

 

Joel Latham

Chief Executive Officer and Managing Director

Level 39, Rialto South Tower
525 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On November 16, 2023, Incannex Healthcare Limited released the announcements attached to this Form 6-K as Exhibit 99.1 and Exhibit 99.2.

 

1

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Incannex Healthcare Limited
     
Date: November 16, 2023 By: /s/ Joel Latham
  Name:  Joel Latham
  Title: Chief Executive Officer and Managing Director

 

2

 

 

INDEX TO EXHIBITS

 

Exhibit No.  
   
99.1 ASX Announcement, dated November 16, 2023 – Court Approves Schemes
   
99.2 Press release, dated November 16, 2023 - Federal Court of Australia approves Incannex’s Re-domiciliation and lodgement of court orders with ASIC

 

 

3

 

 EX-99.1 2 ea188588ex99-1_incannex.htm ASX ANNOUNCEMENT, DATED NOVEMBER 16, 2023 - COURT APPROVES SCHEMES

Exhibit 99.1

 

Date: November 16, 2023

Public Announcement (NASDAQ: IXHL) (ASX: IHL)

 

Not for release to US wire services or distribution in the United States

 

Court Approves Schemes

 

Melbourne, Australia, November 16, 2023 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is pleased to advise that the Federal Court of Australia (Court) has today made orders approving the proposed schemes of arrangement between Incannex and its shareholders and Incannex and its option holders pursuant to which it is proposed that Incannex Healthcare Inc. (Incannex US) will become the new parent entity of the Incannex group (Schemes).

 

Lodgement of Court Orders

 

Pursuant to section 411(10) of the Corporations Act 2001 (Cth), the Schemes will become legally effective upon lodgement of the Court orders with the Australian Securities and Investments Commission (ASIC).

 

It is expected that a copy of the Court’s orders with respect to the Schemes will be lodged with ASIC tomorrow, at which time the Schemes will become legally effective.

 

Incannex intends to apply for Incannex shares to be suspended from trading on ASX, subject to the Schemes becoming legally effective, with effect from the close of trading on Friday, 17 November 2023.

 

Indicative Timetable

 

The key indicative dates and times for the Schemes are as follows:

 

Effective date of the Schemes 17 November 2023
   
Last date of trading of Incannex shares on ASX 17 November 2023
   
Record date for determining entitlements to the consideration under the Schemes 7:00pm (Melbourne time) on 21 November 2023
   
Implementation date for the Schemes 28 November 2023
   
Delisting of Incannex from the official list of ASX 29 November 2023
   
Admission of Incannex US on Nasdaq 29 November 2023
   
First day of trading of Incannex US shares on Nasdaq Expected to commence promptly following the Implementation Date

 

Note: All stated dates and times are indicative only. Any changes to the above timetable will be announced to ASX and Nasdaq and will be available on Incannex's website at https://www.incannex.com/.

 

Incannex Healthcare Limited (ABN: 93 096 635 246)

Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000

P: +61 409 840 786

 

Page 1 | 3

 

 

Date: November 16, 2023

Public Announcement (NASDAQ: IXHL) (ASX: IHL)

 

Small Parcel Holders

 

Shareholders who, based on their holding of Incannex shares on the record date, hold less than a marketable parcel of Incannex shares (being a parcel of shares of less than A$500 based on the closing price on the last day of trading on ASX prior to the record date) (Small Parcel Holders) have until 7:00pm (Melbourne time) on the effective date to submit a Small Parcel Holder Election Form.

 

Further details on the consideration received by Small Parcel Holders and the process for Small Parcel Holders to make an election is set out in section 5.5 of the Scheme Booklet.

 

Further Information

 

If you have any questions in relation to the Schemes, please contact the Incannex Schemes Information Line on 1300 429 179 (within Australia) or +61 2 7208 4522 (outside Australia) Monday to Friday between 8:30am and 7:00pm (Melbourne time).

 

This announcement has been approved for release to ASX by the Incannex Board of Directors.

 

END

 

About Incannex Healthcare Limited

 

Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.

 

U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.

 

Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 29 pending patents. Incannex is listed on the Australian Stock Exchange (ASX) with stock code “IHL” and also has American Depository Shares listed on NASDAQ under code “IXHL”.

 

Website: www.incannex.com.au

Investors: investors@incannex.com.au

 

Incannex Healthcare Limited (ABN: 93 096 635 246)

Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000

P: +61 409 840 786

Page 2 | 3

 

 

Date: November 16, 2023

Public Announcement (NASDAQ: IXHL) (ASX: IHL)

 

Forward-looking statements

 

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates, as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change. Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date after the date of this press release.

 

Not an offer in the United States

 

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

 

Contact Information

 

Incannex Healthcare Limited

Mr Joel Latham

Managing Director and Chief Executive Officer

+61 409 840 786

joel@incannex.com.au

Investor Relations Contact – United States

Alyssa Factor

Edison Group

+1 (860) 573 9637

afactor@edisongroup.com

 

 

Incannex Healthcare Limited (ABN: 93 096 635 246)

Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000

P: +61 409 840 786

 

Page 3 | 3

 

 

 EX-99.2 3 ea188588ex99-2_incannex.htm PRESS RELEASE, DATED NOVEMBER 16, 2023 - FEDERAL COURT OF AUSTRALIA APPROVES INCANNEX'S RE-DOMICILIATION AND LODGEMENT OF COURT ORDERS WITH ASIC

Exhibit 99.2

 

Date: November 16, 2023

Public Announcement (NASDAQ: IXHL) (ASX: IHL)

 

 

FEDERAL COURT OF AUSTRALIA APPROVES INCANNEX’S RE-DOMICILIATION AND LODGEMENT OF COURT ORDERS WITH ASIC

 

Melbourne, November 16, 2023 Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia (“Court”) has today made orders approving the scheme of arrangement in relation to the Company’s proposed re-domiciliation from Australia to the United States (“Scheme”), under which Incannex Healthcare Inc. (“Holdco”) will become the ultimate parent company of Incannex Healthcare Limited following the implementation of the Scheme.

 

It is expected that a copy of the Court’s orders with respect to the Schemes will be lodged with ASIC tomorrow, at which time the Schemes will become legally effective. Incannex has applied to ASX to suspend quotation and trading of Incannex shares, with effect from the close of trading on ASX on November 17, 2023. Incannex’s ADRs, however, will continue to trade on Nasdaq until the implementation date (November 28, 2023).

 

Incannex shareholders and optionholders who hold shares and options on the record date for the Scheme (7:00pm (Melbourne time) on Tuesday, November 21, 2023) will be entitled to receive the Scheme consideration (in accordance with the terms of the Scheme as set out in Section 5.2 and 5.3 of the Scheme Booklet dated October 4, 2023 (“Scheme Booklet”)).  The Scheme consideration will be paid to Scheme Shareholders and Scheme Optionholders (as defined in the Scheme Booklet) on the implementation date.

 

END

 

About Incannex Healthcare Limited

 

Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.

 

U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.

 

Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 29 pending patents. Incannex is listed on the Australian Stock Exchange (ASX) with stock code “IHL” and also has American Depository Shares listed on NASDAQ under code “IXHL”.

 

Website: www.incannex.com.au

Investors: investors@incannex.com.au

 

Forward-looking statements

 

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates, as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change. Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date after the date of this press release.

 

 

Incannex Healthcare Limited (ABN: 93 096 635 246)

Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000

P: +61 409 840 786

Page 1 | 2

 

 

Date: November 16, 2023

Public Announcement (NASDAQ: IXHL) (ASX: IHL)

 

Important Notice

 

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this press release have not been registered under the US Securities Act of 1933, as amended, and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.

 

Contact Information

 

Incannex Healthcare Limited

Mr Joel Latham

Managing Director and Chief Executive Officer

+61 409 840 786

joel@incannex.com.au

Investor Relations Contact – United States

Alyssa Factor

Edison Group

+1 (860) 573 9637

afactor@edisongroup.com

 

 

 

Incannex Healthcare Limited (ABN: 93 096 635 246)

Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000

P: +61 409 840 786

 

Page 2 | 2

 

 

 GRAPHIC 4 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end GRAPHIC 5 ex99-2_001.jpg GRAPHIC begin 644 ex99-2_001.jpg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end